Programs

Athos Therapeutics is currently advancing one preclinical program for patients with Ulcerative Colitis & Crohn’s Disease. Furthermore, Athos is pursuing additional discovery efforts against a range of validated and novel drug targets for patients with different autoimmune diseases.